← Back
Data updated: Mar 10, 2026
NOSTRUM LABS
CardiovascularInfectious DiseaseDermatology
NOSTRUM LABS is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Dermatology.
1993
Since
7
Drugs
-
Trials
41
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
CIPROFLOXACIN HYDROCHLORIDE 2025-12-17
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
ATENOLOL 2025-07-30
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 40%
2 drugs
Infectious Disease 20%
1 drugs
Dermatology 20%
1 drugs
Gastroenterology 20%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Infectious Disease, Dermatology, Gastroenterology
APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Gastroenterology
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology, Cardiovascular
BAUSCH specialty
Dermatology, Cardiovascular, Gastroenterology
Active (4)
Company Info
- First Approval
- 1993-05-28
- Latest
- 2011-09-20
- Applications
- 8
FDA Sponsor Names
NOSTRUM LABSNOSTRUM LABS INC